• The diseases
    • From inflammation to disease
    • Introduction to SAID
    • Genetically undiagnosed SAID
      • STILL DISEASES
      • RECRUITING CENTERS
      • SCHNITZLER
      • BEHCET
      • TAKAYASU
      • KAWASAKI
      • INFLAMMATION OF UNKNOW ORIGIN
      • CHRONIC RECURRENT NON-BACTERIAL OSTEITIS
      • NEUTROPHILIC DERMATOSIS
    • Monogenic SAID
      • MKD
      • FMF
      • CAPS
      • TRAPS
  • The project
    • Overview
    • Detailed Workpackages
    • Consortium
  • The patient page
    • On-going studies
    • Layman summaries
  • The results
    • Publication list
  • Fr|Es|Dk|It ...
ImmunAID ImmunAID ImmunAID
  • The diseases
    • From inflammation to disease
    • Introduction to SAID
    • Genetically undiagnosed SAID
      • STILL DISEASES
      • RECRUITING CENTERS
      • SCHNITZLER
      • BEHCET
      • TAKAYASU
      • KAWASAKI
      • INFLAMMATION OF UNKNOW ORIGIN
      • CHRONIC RECURRENT NON-BACTERIAL OSTEITIS
      • NEUTROPHILIC DERMATOSIS
    • Monogenic SAID
      • MKD
      • FMF
      • CAPS
      • TRAPS
  • The project
    • Overview
    • Detailed Workpackages
    • Consortium
  • The patient page
    • On-going studies
    • Layman summaries
  • The results
    • Publication list
  • Fr|Es|Dk|It ...
ImmunAID ImmunAID ImmunAID
  • The diseases
    • From inflammation to disease
    • Introduction to SAID
    • Genetically undiagnosed SAID
      • STILL DISEASES
      • RECRUITING CENTERS
      • SCHNITZLER
      • BEHCET
      • TAKAYASU
      • KAWASAKI
      • INFLAMMATION OF UNKNOW ORIGIN
      • CHRONIC RECURRENT NON-BACTERIAL OSTEITIS
      • NEUTROPHILIC DERMATOSIS
    • Monogenic SAID
      • MKD
      • FMF
      • CAPS
      • TRAPS
  • The project
    • Overview
    • Detailed Workpackages
    • Consortium
  • The patient page
    • On-going studies
    • Layman summaries
  • The results
    • Publication list
  • Fr|Es|Dk|It ...
  • You are here:  
  • Home
  • The diseases
  • Genetically undiagnosed SAID
  • STILL DISEASES

STILL DISEASE

img still diseases

Video presentation

Adult onset Still Disease

Juvenile onset idiopathic arthritis

  •  Adult onset Still Disease
  •  Juvenile onset idiopathic arthritis

Adult onset Still Disease

Epidemiology

Yellow gender

Gender ratio

1 : 1

Yellow age

Average onset age

16-35 y

Yellow incidence

Incidence

1/105 - 106

Disease presentation

The disease is characterized by intense systemic inflammation with heterogeneous flare frequency. It is usually diagnosed after the elimination of all other possible causes (infection, autoimmunity, cancer)

 

Main clinical symptoms

picto feverRepeated hyperthermia for a few hours in the evening

picto Joint painJoint pain/swelling

picto skin rashSkin rash

Biological signs

Yellow upIncrease in white blood cell counts

Yellow upIncrease in ferritin

Yellow downDecrease in glycosylated ferritin

Therapy

  • Corticosteroids
  • Non-steroidal anti-inflammatory drugs
  • Anti-IL-1 (e.g. Anakinra, Canakinumab)
  • Anti-IL-6 (e.g. Tocitizumab)

Juvenile onset idiopathic arthritis

Epidemiology

Yellow gender

Gender ratio

1 : 1

Yellow age

Average onset age

1-5 y

Yellow incidence

Incidence

0.5-0.9/105

Disease presentation

The disease is characterized by significant extra-articular symptoms and heterogeneous evolution. Some patients will experience no recurrence while other tend to develop polyarticular chronic disease. The diagnosis is based on Edmonton criteria, revised by ILAR.

 

Main clinical symptoms

picto feverRepeated hyperthermia (once or twice daily)

picto Bone inflamJoint pain/swelling on small or large articulations (maybe delayed and increasing with time)

picto skin rashSkin rash (pink macules)

Biological signs

Yellow upIncrease in ferritin

Yellow downDecrease in glycosylated ferritin

Therapy

  • Corticosteroids
  • Non-steroidal anti-inflammatory drugs
  • Anti-IL-1 (e.g. Anakinra, Canakinumab)
  • Anti-IL-6 (e.g. Tocilizumab)

ImmunAID

Grant agreement no: 779295

Funded under: H2020-EU.3.1.1.

ue 80x53

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779295

© ImmunAID 2025, created by CED-WEB.

Cookies infos

Contact Us

The website does not collect any statistical and tracking data. Requests for information through the contact form ensures the protection of personal data by guaranteeing that data collection is carried out with the informed consent of individuals

  • Website & Privacy Policies